動脈粥狀硬化藥物市場－全球產業規模、佔有率、趨勢、機會和預測：按診斷、治療、給藥途徑、最終用戶、地區和競爭格局分類，2021-2031年

全球動脈粥狀硬化治療市場預計將從 2025 年的 191.1 億美元成長到 2031 年的 238.6 億美元，預測期內複合年成長率為 3.77%。

這些藥物的主要目的是透過控制血脂水平和預防血栓形成來抑制動脈斑塊的積聚，從而預防心血管疾病的發生。全球心血管疾病負擔日益加重以及人口老化（老年人罹患動脈粥狀斑塊的風險增加）是推動市場成長的主要因素。美國心臟協會的報告凸顯了這一緊迫性，該報告預測，到2024年，心血管疾病將導致全球每年約1,991萬人死亡。這項數據有力地顯示了持續的藥物介入和旨在穩定斑塊的治療方案的重要性。

然而，市場面臨一個重大障礙：重磅藥物的專利到期。隨後，價格低廉的學名藥上市，顯著降低了現有品牌藥物的市場佔有率和收入潛力。因此，藥物研發人員面臨越來越大的創新壓力，但高昂的研發成本和嚴格的監管要求往往會延長下一代動脈粥狀硬化治療藥物的商業化。

市場促進因素

全球心血管疾病和高血脂症率的不斷上升是動脈粥狀硬化治療市場的主要驅動力。隨著久坐不動的生活方式和不良飲食習慣日益普遍，動脈斑塊積聚和血脂異常的發生率也隨之增加，導致需要藥物治療的患者群體龐大。這種日益加重的疾病負擔推動了對降血脂療法（例如他汀類藥物和聯合用藥）的需求，以預防中風和心肌梗塞等嚴重後果。根據美國心臟協會 (AHA) 於 2024 年 1 月發布的《2024 年心臟病和中風統計更新》，2017 年至 2020 年間，美國約有 1.279 億成年人患有某種形式的心血管疾病。如此高的盛行率促使醫療保健提供者積極開立處方藥，從而確保了製藥商穩定的收入來源。

同時，新型療法的進步，尤其是PCSK9抑制劑，正在重塑市場格局。製藥公司正大力投資研發，力求為無法耐受傳統他汀類藥物或需要進一步降低血脂的患者推出新一代生物製藥和口服藥物。例如，2024年7月，新阿姆斯特丹製藥公司發表了其3期BROOKLYN臨床試驗的結果，顯示新型CETP抑制劑obicetrapib在第84天時使低密度脂蛋白膽固醇水平較安慰劑對照組降低了36.3%。這些先進療法的商業性成功也反映在財務表現上。根據安進公司於2024年10月公佈的2024年第三季財務報告，PCSK9抑制劑Repata的銷售額達到5.67億美元，年增40%，顯示創新技術透過滿足高風險族群的需求來推動市場價值的重要性。

市場挑戰

重磅療法專利到期對全球動脈粥狀硬化治療市場的成長構成重大阻礙。隨著關鍵抗血栓和降血脂藥物的專利保護期結束，學名藥價格遠低於品牌藥。這種轉變將顯著降低市場估值，因為專利藥帶來的高額利潤將被學名藥低利潤、高銷售量的經濟模式所取代。因此，原廠藥生產商面臨收入快速下滑的困境，限制了整個產業的財務擴張，並減少了可用於高風險研發舉措的再投資資金。

這項財務挑戰的規模龐大且可量化。 2024年，可及藥品協會報告稱，學名藥在上年度為心臟病患者節省了1,181億美元。這一數字有力地說明了品牌藥產業的巨大價值流失。這種具成本效益替代品的廣泛應用抑制了市場的整體獲利潛力，使得該產業難以維持其以往依賴成熟產品線的傳統成長模式。

市場趨勢

Glucagon-Like Peptide-1(GLP-1)促效劑在心血管疾病預防領域的應用拓展，代表著動脈粥狀硬化治療市場的變革性趨勢。這些療法最初核准用於體重管理和糖尿病治療，如今正擴大被用於降低已確診動脈粥狀硬化性心血管疾病患者發生重大不利事件的風險。這項轉變認知到全身代謝因素會加劇動脈斑塊的不穩定性，並將治療目標從單純的血脂管理擴展到全面管理更廣泛的代謝和發炎風險。為了支持這一轉變，諾和諾德在其2024年3月的新聞稿「Wegovy核准在美國用於降低超重或肥胖患者的心血管風險」中宣布，臨床試驗表明，2.4毫克Semaglutide可使已知患有心血管疾病的超重或肥胖成人發生重大不利事件的風險降低20%。

同時，針對降低脂蛋白(a)水平的標靶治療的研發正在填補精準醫療領域的一個重要空白。高水平的Lp(a)是一種遺傳決定的風險因素，它獨立於低密度脂蛋白膽固醇水平促進動脈粥樣硬化，且通常對標準他汀類藥物治療無效。製藥研發人員正在利用先進的小干擾RNA (SMRNA)技術來沉默負責產生這些動脈粥狀硬化顆粒的基因，為心血管風險較高的患者帶來了新的希望。為了支持這項療法的有效性，Silence Therapeutics公司在2024年5月發布的題為「Silence Therapeutics公佈Zelurasiran II期研究第36週的積極數據」的新聞稿中宣布，其在研藥物Zelurasiran在最高兩個劑量組的受試者中，於第36週時使脂蛋白位數(a)水平中降低了90%以上。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球動脈粥狀硬化治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 透過診斷（踝臂指數、多普勒超音波、心臟超音波圖、心電圖、血液檢查、其他）
  • 依治療方法（藥物治療、手術、其他）
  • 依給藥途徑（口服、腸外、其他）
  • 按最終使用者（醫院/診所、門診護理中心、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美動脈硬化藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章 歐洲動脈硬化藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章 亞太地區動脈硬化治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章 中東和非洲動脈硬化治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美動脈硬化治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球動脈粥狀硬化藥物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Merck & Co. Inc.
• Pfizer Inc.
• Eli Lilly and Co.
• Sanofi SA
• AstraZeneca Plc
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• GSK Plc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Atherosclerosis Drugs Market is projected to expand from USD 19.11 Billion in 2025 to USD 23.86 Billion by 2031, registering a CAGR of 3.77% throughout the forecast period. These pharmaceutical agents are designed to reduce the accumulation of arterial plaque, principally by managing lipid concentrations and preventing thrombus formation to avert cardiovascular incidents. The market's growth is fundamentally underpinned by the mounting global burden of cardiovascular diseases alongside an aging population increasingly prone to arterial hardening. Highlighting this urgency, the American Heart Association reported in 2024 that cardiovascular diseases were responsible for approximately 19.91 million deaths worldwide each year, a statistic that emphasizes the critical need for sustained pharmacological interventions and therapeutic regimens aimed at plaque stabilization.

However, the market faces a substantial obstacle in the form of patent expirations for major blockbuster drugs. The subsequent introduction of affordable generic alternatives significantly diminishes the market share and revenue potential of established branded therapies. As a result, pharmaceutical developers are under mounting pressure to innovate, although the high costs of development and stringent regulatory requirements frequently prolong the timeline for bringing next-generation atherosclerosis treatments to commercial realization.

Market Driver

The escalating global incidence of cardiovascular diseases and hyperlipidemia acts as the primary engine driving the atherosclerosis drugs market. As sedentary lifestyles and suboptimal dietary habits become increasingly common, the frequency of arterial plaque buildup and lipid irregularities has risen, resulting in a vast patient population requiring pharmacological treatment. This growing disease burden necessitates a higher volume of lipid-lowering therapies, such as statins and combination drugs, to avert critical outcomes like strokes and myocardial infarctions. According to the American Heart Association's "2024 Heart Disease and Stroke Statistics Update" from January 2024, an estimated 127.9 million adults in the United States were affected by some form of cardiovascular disease between 2017 and 2020, a prevalence that compels healthcare providers to aggressively prescribe medications, ensuring steady revenue streams for manufacturers.

Concurrently, the market is being reshaped by advancements in novel therapeutics, particularly the robust development of PCSK9 inhibitors. Pharmaceutical entities are heavily investing in research and development to bring next-generation biologics and oral options to market for patients who cannot tolerate traditional statins or require further lipid reduction. For example, NewAmsterdam Pharma reported in July 2024 within their "Phase 3 BROOKLYN Clinical Trial Results" that the novel CETP inhibitor obicetrapib realized a 36.3% decrease in low-density lipoprotein cholesterol by day 84 relative to a placebo. The commercial success of such advanced treatments is reflected in financial performance; Amgen's "Third Quarter 2024 Financial Results" from October 2024 indicated that sales for the PCSK9 inhibitor Repatha rose by 40% year-over-year to reach $567 million, demonstrating how these innovations drive market value by meeting the needs of high-risk populations.

Market Challenge

The expiration of patents for key blockbuster therapies presents a formidable barrier to the financial growth of the Global Atherosclerosis Drugs Market. As exclusivity periods for major antithrombotic and lipid-regulating agents come to an end, the sector encounters a surge of generic competitors that are priced substantially lower than branded originals. This shift causes a marked decline in market valuation, as the significant revenues generated by exclusive proprietary drugs are supplanted by the low-margin, high-volume economics typical of generic formulations. Consequently, original manufacturers face rapid revenue erosion, which suppresses the sector's overall monetary expansion and limits the funds available for reinvesting into high-risk research initiatives.

The magnitude of this financial challenge is both significant and measurable. In 2024, the Association for Accessible Medicines reported that generic medications delivered $118.1 billion in savings for patients with heart disease over the previous year, a figure that effectively illustrates the massive value diverted from the branded pharmaceutical sector. This widespread uptake of cost-efficient alternatives curtails the overall revenue potential of the market, creating a landscape where the industry struggles to maintain historical growth trajectories that relied heavily on established product lines.

Market Trends

The expansion of labels for Glucagon-Like Peptide-1 agonists to include cardiovascular prevention marks a transformative trend within the atherosclerosis drugs market. Although initially approved for weight management and diabetes, these therapeutics are increasingly adopted to lower the risk of major adverse cardiovascular events in individuals with established atherosclerotic cardiovascular disease. This transition recognizes the systemic metabolic factors that aggravate arterial plaque instability, extending treatment goals beyond simple lipid management to encompass broader metabolic and inflammatory risks. Underscoring this shift, Novo Nordisk announced in a March 2024 press release titled "Wegovy approved in the US for cardiovascular risk reduction in people with overweight or obesity" that clinical trials showed semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% in overweight or obese adults with known cardiovascular disease.

In parallel, the creation of targeted therapies aimed at lowering Lipoprotein(a) is fulfilling a crucial unmet need in precision medicine. Elevated Lipoprotein(a) serves as a genetically determined risk factor that promotes atherosclerosis independently of low-density lipoprotein cholesterol levels and generally does not respond to standard statin treatments. Pharmaceutical developers are utilizing advanced small interfering RNA technologies to suppress the genes responsible for generating this atherogenic particle, providing new prospects for patients with high residual cardiovascular risk. Validating this approach, Silence Therapeutics revealed in May 2024, within the "Silence Therapeutics Announces Positive 36-Week Data from Phase 2 Study of Zerlasiran," that the investigational drug zerlasiran attained a median Lipoprotein(a) reduction of 90% or more at week 36 for participants in the top two dosage cohorts.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Merck & Co. Inc.
• Pfizer Inc.
• Eli Lilly and Co.
• Sanofi S.A.
• AstraZeneca Plc
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• GSK Plc

Report Scope

In this report, the Global Atherosclerosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Atherosclerosis Drugs Market, By Diagnosis

• Ankle-brachial Index
• Doppler Ultrasound
• Echocardiogram
• Electrocardiogram
• Blood Tests
• Others

Atherosclerosis Drugs Market, By Treatment

• Medication
• Surgery
• Others

Atherosclerosis Drugs Market, By Route of Administration

• Oral
• Parenteral
• Others

Atherosclerosis Drugs Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Atherosclerosis Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Atherosclerosis Drugs Market.

Available Customizations:

Global Atherosclerosis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Atherosclerosis Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Diagnosis (Ankle-brachial Index, Doppler Ultrasound, Echocardiogram, Electrocardiogram, Blood Tests, Others)
  • 5.2.2. By Treatment (Medication, Surgery, Others)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Atherosclerosis Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Diagnosis
  • 6.2.2. By Treatment
  • 6.2.3. By Route of Administration
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Atherosclerosis Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Diagnosis
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Atherosclerosis Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Diagnosis
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Atherosclerosis Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Diagnosis
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By End User

7. Europe Atherosclerosis Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Diagnosis
  • 7.2.2. By Treatment
  • 7.2.3. By Route of Administration
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Atherosclerosis Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Diagnosis
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End User
  • 7.3.2. France Atherosclerosis Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Diagnosis
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Atherosclerosis Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Diagnosis
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Atherosclerosis Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Diagnosis
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Atherosclerosis Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Diagnosis
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By End User

8. Asia Pacific Atherosclerosis Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Diagnosis
  • 8.2.2. By Treatment
  • 8.2.3. By Route of Administration
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Atherosclerosis Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Diagnosis
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End User
  • 8.3.2. India Atherosclerosis Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Diagnosis
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Atherosclerosis Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Diagnosis
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Atherosclerosis Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Diagnosis
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Atherosclerosis Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Diagnosis
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By End User

9. Middle East & Africa Atherosclerosis Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Diagnosis
  • 9.2.2. By Treatment
  • 9.2.3. By Route of Administration
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Atherosclerosis Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Diagnosis
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Atherosclerosis Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Diagnosis
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Atherosclerosis Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Diagnosis
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End User

10. South America Atherosclerosis Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Diagnosis
  • 10.2.2. By Treatment
  • 10.2.3. By Route of Administration
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Atherosclerosis Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Diagnosis
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Atherosclerosis Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Diagnosis
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Atherosclerosis Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Diagnosis
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Atherosclerosis Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Merck & Co. Inc.
• 15.4. Pfizer Inc.
• 15.5. Eli Lilly and Co.
• 15.6. Sanofi S.A.
• 15.7. AstraZeneca Plc
• 15.8. Bayer AG
• 15.9. Regeneron Pharmaceuticals Inc.
• 15.10. GSK Plc

16. Strategic Recommendations

17. About Us & Disclaimer